FDA

FDA Posts More Than 100 Warning Letters in Drug Ad Crackdown, Targeting Hims, Lilly and Novo

The push follows a directive from President Trump to ensure drug promotions are truthful, expanding oversight to telehealth marketing of compounded GLP-1 products.